These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
45. [Biochemistry of the regression and latent phase of porphyria cutanea tarda]. Peschlow I; Schlenzka K Dermatol Monatsschr; 1983 Feb; 169(2):85-91. PubMed ID: 6840368 [No Abstract] [Full Text] [Related]
46. [Combination therapy of porphyria cutanea tarda using chloroquine and bloodletting therapy]. Horkay I; Nagy E Z Hautkr; 1980 Jun; 55(12):813-6. PubMed ID: 7415362 [TBL] [Abstract][Full Text] [Related]
47. The ether soluble porphyrins found in urine in acute porphyria and porphyria cutanea tarda. ERIKSEN L; ERIKSEN N; HAAVALDSEN S Scand J Clin Lab Invest; 1962; 14():6-10. PubMed ID: 13890580 [No Abstract] [Full Text] [Related]
48. Pilot survey of urinary porphyrins from persons transiently exposed to a PCB transformer fire. Osterloh J; Cone J; Harrison R; Wade R; Becker C J Toxicol Clin Toxicol; 1986-1987; 24(6):533-44. PubMed ID: 3106647 [TBL] [Abstract][Full Text] [Related]
49. Abnormal urinary coproporphyrin levels in patients infected by hepatitis C virus with or without human immunodeficiency virus. A study of 177 patients. Cribier B; Rey D; Uhl G; Le Coz C; Hirth C; Libbrecht E; Vetter D; Lang JM; Stoll-Keller F; Grosshans E Arch Dermatol; 1996 Dec; 132(12):1448-52. PubMed ID: 8961873 [TBL] [Abstract][Full Text] [Related]
50. Urinary porphyrin excretion in hepatitis C infection. Vogeser M; Jacob K; Zachoval R Clin Chem Lab Med; 1999 Aug; 37(8):799-804. PubMed ID: 10536928 [TBL] [Abstract][Full Text] [Related]
51. [Effects of the treatment of porphyria cutanea tarda on the changes of the urinary porphyrin pattern (determined by high performance liquid chromatography) and histopathological aspects of the liver]. Cainelli T; Marchesi L; De Padova C; Reseghetti A G Ital Dermatol Venereol; 1984; 119(3):171-4. PubMed ID: 6746012 [No Abstract] [Full Text] [Related]
52. Reduction of porphyrin excretion in porphyria variegata by propranolol. A case report. Blum I; Atsmon A S Afr Med J; 1976 May; 50(23):898-9. PubMed ID: 935983 [TBL] [Abstract][Full Text] [Related]
53. Urinary porphyrin excretion in a human population highly exposed to hexachlorobenzene. Herrero C; Ozalla D; Sala M; Otero R; Santiago-Silva M; Lecha M; To-Figueras J; Deulofeu R; Mascaró JM; Grimalt J; Sunyer J Arch Dermatol; 1999 Apr; 135(4):400-4. PubMed ID: 10206046 [TBL] [Abstract][Full Text] [Related]
54. Porphyria cutanea tarda. A study of the effect of phlebotomy. Epstein JH; Redeker AG N Engl J Med; 1968 Dec; 279(24):1301-4. PubMed ID: 5697519 [No Abstract] [Full Text] [Related]
55. Serum organochlorines and urinary porphyrin pattern in a population highly exposed to hexachlorobenzene. Sunyer J; Herrero C; Ozalla D; Sala M; Ribas-Fitó N; Grimalt J; Basagaña X Environ Health; 2002 Jul; 1(1):1. PubMed ID: 12495451 [TBL] [Abstract][Full Text] [Related]
56. Effect of chloroquine on hepatic uroporphyrin metabolism in patients with porphyria cutanea tarda. Felsher BF; Redeker AG Medicine (Baltimore); 1966 Nov; 45(6):575-83. PubMed ID: 5925910 [No Abstract] [Full Text] [Related]
58. The role of iron in the pathogenesis of porphyria cutanea tarda. An in vitro model. Kushner JP; Lee GR; Nacht S J Clin Invest; 1972 Dec; 51(12):3044-51. PubMed ID: 4640947 [TBL] [Abstract][Full Text] [Related]
59. Urinary porphyrin excretion in children is associated with exposure to organochlorine compounds. Sunyer J; Alvarez-Pedrerol M; To-Figueras J; Ribas-Fitó N; Grimalt JO; Herrero C Environ Health Perspect; 2008 Oct; 116(10):1407-10. PubMed ID: 18941586 [TBL] [Abstract][Full Text] [Related]
60. Biochemical diagnosis and monitoring therapeutic modulation of disease activity in an unusual case of congenital erythropoietic porphyria. Mukerji SK; Pimstone NR; Gandhi SN; Tan KT Clin Chem; 1985 Dec; 31(12):1946-51. PubMed ID: 4064282 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]